Is Stelara Approved for Ulcerative Colitis?
Yes, Stelara (ustekinumab) is FDA-approved for treating moderately to severely active ulcerative colitis in adults. The approval came in October 2020, based on data from the UNIFI Phase 3 trial showing clinical remission in 15.5-15.6% of patients at week 8 (induction) and 44% at week 44 (maintenance), compared to 5.3% and 24% on placebo.[1][2]
How Does Stelara Work for Ulcerative Colitis?
Stelara targets interleukins 12 and 23, cytokines involved in inflammation. Patients receive an IV infusion for induction, followed by subcutaneous injections every 8 weeks for maintenance. It's used after inadequate response to TNF blockers like Humira or Remicade.[1]
Who Qualifies for Stelara Treatment?
It's for adults 18+ with moderate-to-severe active disease confirmed by endoscopy and biomarkers. Not for mild cases or initial therapy—guidelines recommend it as second- or third-line after conventional treatments fail.[2][3]
Common Side Effects and Risks
Patients report upper respiratory infections (23%), headache (11%), and fatigue (6%). Serious risks include infections (e.g., TB reactivation), malignancy, and hypersensitivity. Long-term data show no new safety signals up to 3 years.[1][2] Black box warning for infections and malignancy applies.
How Does Stelara Compare to Other UC Drugs?
| Drug | Mechanism | Remission Rate (Maintenance) | Dosing Frequency |
|------|-----------|------------------------------|------------------|
| Stelara | IL-12/23 inhibitor | 44% (week 44) [1] | Every 8 weeks SC |
| Entyvio (vedolizumab) | Gut-selective integrin inhibitor | 42-52% (week 52) [4] | Every 8 weeks IV |
| Humira (adalimumab) | TNF inhibitor | 17-30% (week 56) [5] | Every 2 weeks SC |
| Xeljanz (tofacitinib) | JAK inhibitor | 34-41% (week 52) [6] | Daily oral |
Stelara offers convenience over IV-heavy options but has slower onset than JAKs. Head-to-head trials are limited.
When Does Stelara's Patent Expire for UC?
Core patents expire around 2023-2025, but method-of-use patents for UC extend exclusivity to 2032 in some cases. Biosimilars like those from Samsung Bioepis are in late-stage development, with launches possible post-2030 pending litigation.[7][8]
What Do Patients Ask About Switching to Stelara?
Many search for real-world remission durability (about 50% at 1 year) and injection site reactions (minimal). It's pregnancy category B, with limited data—use if benefits outweigh risks.[2][9]
Sources:
[1]: FDA Stelara Label
[2]: Janssen Stelara UC Page
[3]: AGA UC Guidelines 2020
[4]: Entyvio UNIFI Trial
[5]: Humira ULTRA 2 Trial
[6]: Xeljanz OCTAVE Trials
[7]: DrugPatentWatch Stelara
[8]: FDA Orange Book
[9]: Crohn's & Colitis Foundation